This inhibits the cyclin D-CDK4/6 complex as well as the cyclin E-CDK2 complex, which usually triggers the transition from the G1 stage to the S-phase, and this regulatory p53-mechanism is proven in different CRC cell lines such as SW480 and HT-29 [137]. This evidence concerns the gene TP53 and colorectal carcinoma.